A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2859-2868

  Benton, E C ^a   Crichton, S ^b   Talpur, R ^c   Agar, N S ^a   Fields, P A ^d   Wedgeworth, E ^a   Mitchell, T J ^a   Cox, M ^e   Ferreira, S ^a   Liu, P ^c   Robson, A ^a   Calonje, E ^a   Stefanato, C M ^a   Wilkins, B ^d   Scarisbrick, J ^a   Wain, E M ^a   Child, F ^a   Morris, S ^a   Duvic, M ^c   Whittaker, S J ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e Integrated Cancer Research (ICARSIS)   (United Kingdom)

Author keywords

Cutaneous lymphoma; Mycosis fungoides; Prognostic index; Sezary syndrome

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEZARY SYNDROME; VALIDATION STUDY;

CUTANEOUS LYMPHOMA; MYCOSIS FUNGOIDES; PROGNOSTIC INDEX; SEZARY SYNDROME;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEZARY SYNDROME; SKIN NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881097093     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.018     Document Type: Article

References (31)

1. P.T. Bradford, S.S. Devessa, W.F. Anderson, and J.R. Toro Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases Blood 113 2009 5064 5073
2. R. Willemze, E.S. Jaffe, and G. Burg WHO-EORTC classification for cutaneous lymphomas Blood 105 2005 3768 3785
3. N. Agar, E. Wedgeworth, and S. Crichton Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: a validation of the revised ISCL/EORTC proposal J Clin Oncol 28 2010 4730 4739
4. F. Trautinger, R. Knobler, and R. Willemze EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome Eur J Cancer 42 2006 1014 1030
5. R. Dummer, and M. Dreyling ESMO guidelines working group: primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 19 Suppl. 2 2008 72 76
6. S.M. Horwitz, E.A. Olsen, M. Duvic, P. Porcu, and Y.H. Kim Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach J Natl Compr Canc Netw 6 2008 436 442
7. P.A. Bunn, and S.I. Lamberg Report of the committee on staging and classification of cutaneous T-cell lymphomas Cancer Treat Rep 63 1979 725 728
8. E. Olsen, E. Vonderheid, and N. Pimpinelli Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 1713 1722
9. Y.H. Kim, H.L. Liu, S. Mraz-Gernhard, A. Varghese, and R.T. Hoppe Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression Arch Dermatol 139 2003 857 866
10. S.J. Whittaker, and F.M. Foss Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma Cancer Treat Rev 33 2007 146 160
11. S.J. Whittaker, J.R. Marsden, M. Spittle, and R. Russell-Jones Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas Br J Dermatol 149 2003 1095 1107
12. < http://www.nccn.org/professionals/physician-gls/f-guidelines.asp >.
13. P. Solal-Celigny, P. Roy, and P. Colombat Follicular lymphoma international prognostic index Blood 104 2004 1258 1265
14. M. Shipp, D.P. Harrington, and J.R. Anderson A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project N Engl J Med 329 1993 987 994
15. D. Hasenclever, and V. Diehl A prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease N Engl J Med 339 1998 1506 1514
16. A. Gallamini, C. Stelitano, and R. Calvi Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood 103 2004 2474 2479
17. M.A. Weinstock, and J.F. Reynes The changing survival of patients with mycosis fungoides: a population based assessment of trends in the United States Cancer 85 1999 208 212
18. H.S. Zackheim, S. Amin, M. Kashani-Sabet, and A. McMillan Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients J Am Acad Dermatol 40 1999 418 425
19. E. Diamandidou, M. Colome, L. Fayad, M. Duvic, and R. Kurzrock Prognostic factor analysis in mycosis fungoides/Sezary syndrome J Am Acad Dermatol 40 1999 914 924
20. B. Vergier, A. de Muret, and M. Beylot-Barry Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases Blood 95 2000 2212 2218
21. E. Diamandidou, M. Colome-Grimmer, L. Fayad, M. Duvic, and R. Kurzrock Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis Blood 92 1998 1150 1159
22. J.J. Scarisbrick, S. Whittaker, and A.V. Evans Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma Blood 97 2001 624 630
23. R.C. Beljaards, and R. Willemze The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas Br J Dermatol 126 1992 596 602
24. E.M. Wain, G.E. Orchard, S.J. Whittaker, M. Spittle, and R. Russell-Jones Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study Cancer 98 2003 2282 2290
25. S.O. Arulogun, H.M. Prince, and J. Ng Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation Blood 112 2008 3082 3087
26. E.C. Vonderheid, J. Pena, and P. Nowell Sezary cell counts in erythrodermic cutaneous T cell lymphoma: implications for prognosis and staging Leuk Lymphoma 47 2006 1841 1856
27. M.F. Benner, P.M. Jansen, M.H. Vermeer, and R. Willemze Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases Blood 119 7 2012 1643 1649
28. C.D. Klemke, U. Mansmann, N. Poenitz, E. Dippel, and S. Goerdt Prognostic factors and prediction of prognosis by the CTCL severity index in mycosis fungoides and Sézary syndrome Br J Dermatol 153 2005 118 124
29. M.H. Schmid, P. Bird, R. Dummer, W. Kempf, and G. Burg Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept Arch Dermatol 135 1999 1204 1208
30. R. Talpur, L. Singh, and S. Daulat Long-term outcomes of 1263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009 Clin Cancer Res 18 2012 5051 5060
31. E.A. Olsen, S. Whittaker, and Y.H. Kim Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer J Clin Oncol 29 2011 2598 2607